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ARTICLE OPEN
Antibody responses to the RTS,S/AS01E vaccine and
Plasmodium falciparum antigens after a booster dose within
the phase 3 trial in Mozambique
Lina Sanchez1,2, Marta Vidal1, Chenjerai Jairoce1,3, Ruth Aguilar1, Itziar Ubillos1, Inocencia Cuamba3, Augusto J. Nhabomba3,
Nana Aba Williams1, Núria Díez-Padrisa1, David Cavanagh4, Evelina Angov5, Ross L. Coppel6, Deepak Gaur7,8, James G. Beeson9,
Sheetij Dutta5, Pedro Aide 3, Joseph J. Campo2,3, Gemma Moncunill1,3,10✉ and Carlota Dobaño 1,3,10✉
The RTS,S/AS01E vaccine has shown consistent but partial vaccine efficacy in a pediatric phase 3 clinical trial using a 3-dose
immunization schedule. A fourth-dose 18 months after the primary vaccination was shown to restore the waning efficacy. However,
only total IgG against the immunodominant malaria vaccine epitope has been analyzed following the booster. To better
characterize the magnitude, nature, and longevity of the immune response to the booster, we measured levels of total IgM, IgG,
and IgG1-4 subclasses against three constructs of the circumsporozoite protein (CSP) and the hepatitis B surface antigen (HBsAg,
also present in RTS,S) by quantitative suspension array technology in 50 subjects in the phase 3 trial in Manhiça, Mozambique. To
explore the impact of vaccination on naturally acquired immune responses, we measured antibodies to P. falciparum antigens not
included in RTS,S. We found increased IgG, IgG1, IgG3 and IgG4, but not IgG2 nor IgM, levels against vaccine antigens 1 month after
the fourth dose. Overall, antibody responses to the booster dose were lower than the initial peak response to primary immunization
and children had higher IgG and IgG1 levels than infants. Higher anti-Rh5 IgG and IgG1-4 levels were detected after the booster
dose, suggesting that RTS,S partial protection could increase some blood stage antibody responses. Our work shows that the
response to the RTS,S/AS01E booster dose is different from the primary vaccine immune response and highlights the dynamic
changes in subclass antibody patterns upon the vaccine booster and with acquisition of adaptive immunity to malaria.
npj Vaccines            (2020) 5:46 ; https://doi.org/10.1038/s41541-020-0192-7
INTRODUCTION
Despite the great reduction in malaria cases in the last 15 years,
thanks to the combination of multiple control measures, it is
estimated that 219 million malaria cases and 435,000 deaths
occurred in 2017, mostly associated with Plasmodium falciparum1.
Importantly, 90% of these deaths concentrated in sub-Saharan
Africa and a large proportion occurred in children under 5 years.
Owing to the concerning rise of parasite resistance to antimalarial
drugs and vector resistance to insecticides1,2 and stalling progress
in reducing malaria since 20161,2, integration of a malaria vaccine
with other preventive measures will be a useful addition to control
disease burden in the future.
Currently, the pre-erythrocytic RTS,S/AS01E vaccine is the most
advanced, having shown consistent but partial vaccine efficacy
(VE) that wanes over time and is less effective in infants compared
to children3. RTS,S/AS01E contains a fusion protein including the
central tandem repeat (NANP) and the C-terminal (C-term) regions
of the P. falciparum circumsporozoite protein (CSP), and the
hepatitis B virus surface antigen (HBsAg). It is expressed together
with HBsAg, and injected in combination with the AS01 adjuvant
system4. The vaccine was tested in a phase 3 clinical trial of a 3-
dose immunization schedule (month [M] 0, M1 and M2) with a
fourth dose 18 months after primary vaccination (M20)3, with the
booster dose partly restoring the waning VE. Specifically, VE for
the 3-dose immunization schedule was 35.2% in children and
20.3% in infants up to M32 of the study, but VE waned over time
with a VE of 16.1 and 7.6%, respectively, when considering only
the period from M20 to M32. In children and infants who received
the booster dose, waning VE was restored to overall levels of 43.9
and 27.8%, respectively3. In order to understand why protection
offered by RTS,S is suboptimal and continue efforts to improve it,
there is a need to decipher the mechanisms of protection elicited
by the vaccine. It has been shown that antibody levels are
involved in the vaccine-induced immunity, but they do not fully
explain the protective effect of the vaccine5,6. Thus far, the study
of antibody response in trials performed in endemic areas has
been largely focused on IgG levels against the NANP repeat region
of CSP, with the exception of our previous work assessing more
generally subclass responses to NANP and to other antigens after
primary vaccination in the phase 3 trial7–9.
Characterizing responses by other antibody isotypes, sub-
classes, and responses to different epitopes may provide in depth
understanding of the immune response to the vaccine and the
mode of action. Antibody levels are not the sole means to
determine vaccine mechanisms of action. Characteristics like the
balance between isotypes or subclasses of the antibodies are
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important because of their varying effector functions10. For
instance, some IgG subclasses act as cytophilic while others have
non-cytophilic functions10, influencing the roles of Fc-mediated
functions such as complement fixation and phagocytosis11.
Determining which type of response is detrimental or beneficial
could further inform which responses could be modified to
enhance the efficacy of the vaccine.
The epitope specificity of the antibody response is also relevant.
There is clear evidence that NANP is related to VE6 but other
regions could also mediate protection. Avidity of IgG to the CSP
C-term has been associated with protection in African children12,
and C-term and not the NANP-repeat-specific antibodies have
been reported to be the main mediators of phagocytic activity in
naive adults13. Furthermore, antibodies to both C-term and NANP-
repeat can mediate complement fixation in children, suggesting
both regions are important for functional activity14,15.
Additionally, studying the response to P. falciparum blood stage
antigens not present in the vaccine is relevant to determine the
effect of the vaccine on naturally acquired immunity (NAI),
developed from continuous parasite exposure. It has been
hypothesized that vaccination could (1) decrease NAI by reducing
the exposure to the parasite, which could mean individuals are left
vulnerable in the long term due to the waning efficacy of the
vaccine3, as predicted for other malaria prevention tools16, or (2)
increase NAI by allowing subclinical exposure to the parasite due
to the partial efficacy of the vaccine9,17.
Here, we used samples from the phase 3 trial at the time of the
booster dose (M20) and onwards from a subgroup of subjects in
Manhiça, Mozambique, to characterize the effect of the RTS,S/
AS01E booster dose on different antibody responses. We
evaluated total IgM, IgG and IgG1-4 subclasses to vaccine and
vaccine-unrelated P. falciparum blood stage antigens. Data were
combined with those from the primary vaccine response
previously assessed7–9 to display the kinetics from baseline (M0)
until M32.
RESULTS
Short- and long-term booster immunogenicity
The RTS,S/AS01E booster dose increased IgG, IgG1, IgG3, and IgG4
levels against all vaccine antigens 1 month (M21) after its
administration (M20), but it did not increase IgG2 nor IgM levels
(Figs. 1 and 2; and Supplementary Table 1). The increase in
antibody levels was significant both when comparing the levels
pre-boost at M20 and M21 of the same individual, and when
comparing the levels at post-boost M21 of the RTS,S booster
group (R3R) to those of the individuals who did not receive a
booster (R3C), except for IgG3 CSP NANP and IgG3 CSP full length
(FL) for the latter comparison. At M21, the highest levels were
against FL CSP, followed by the CSP NANP region, the CSP C-term
and HBsAg. The predominant subclass was IgG1 followed by IgG3,
then lower levels of IgG2 and least for IgG4.
Longer-term immunogenicity was measured 1 year after the
administration of the booster (M32). IgG and IgG1 (but not IgG3)
levels against vaccine antigens in the R3R group remained above
the R3C group, except for IgG1 NANP (Figs. 1 and 2; and
Supplementary Table 1). Similar to the pattern at M21, IgG2 and
IgM levels were not higher in R3R at M32. For IgG4, levels were
significantly higher in R3R compared to R3C only for CSP C-term
and HBsAg. In comparison to the group that did not receive any
RTS,S dose (C3C), the R3R and R3C groups levels at M32 remained
higher for most antigens and IgG subclasses, except HBsAg IgG2
and IgG3, and NANP IgG3.
Fig. 1 RTS,S/AS01E booster and long-term immunogenicity against vaccine antigens: total IgG, IgG1-2 subclasses for CSP constructs and
HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with
medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3+ 1.5*IQR, lower whisker as the largest
between minimum × value and Q1 – 1.5*IQR, and log10(geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the
booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each
timepoint. Only p-values < 0.05 after adjustment for multiple testing are shown. The y-axis is in logarithm 10 scale. R3R (green): three doses of
RTS,S/AS01E and a RTS,S/AS01E booster. R3C (red): three doses of RTS,S/AS01E and a comparator booster. C3C (blue): three doses of a
comparator vaccine and a comparator booster.
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Antibody kinetics through the entire study follow-up
When comparing the booster response (M21) to the primary
vaccination response (M3), the group that received the booster had
a lower peak in IgG, IgG1 and IgG3 levels after the booster than
after primary vaccination (Figs. 3 and 4; and Supplementary Figs. 1
and 2). In contrast, IgG4 levels against CSP constructs showed
higher levels after the booster dose than after primary vaccination,
and overall levels increased in time. The opposite happened with
HBsAg where IgG4 levels decreased with time and were higher at
M3 than at M21. Although primary vaccination increased IgG2 and
IgM levels, the booster dose did not increase them.
The decrease in anti-CSP levels from primary vaccination to M20
was larger for IgG3 than for IgG and IgG1; the mean decreases for
anti-NANP IgG and IgG1 was around 1.5 log10 median fluorescent
intensity (MFI) while for IgG3 it was around 2.5 log10MFI. IgG2
levels remained more stable after the primary vaccination and did
not increase or decrease vastly after M3. Remarkably, IgG4 levels
against CSP FL and C-term at M20 were slightly higher than levels
at M3 although this effect was not observed in the C3C group.
The levels of IgG and IgG1-4 to CSP in RTS,S/AS01E vaccination
groups (R3), with or without booster, were higher for most post-
vaccination time points than the levels in the comparator group.
IgM levels were higher only at M3 in the R3 groups compared to
the C3C group.
Factors affecting immunogenicity
Age. Children who received RTS,S/AS01E either with or without a
booster had higher IgG and IgG1 levels against CSP antigens than
infants throughout the study period (Supplementary Figs. 1–6 and
Supplementary Table 2). Without booster, IgG3 levels to NANP and
FL CSP, but not C-term, were higher in children than infants. In
contrast, we did not detect differences in IgG3 levels between age
groups after booster immunization. Most of the differences
observed were not statistically significant but there were
consistent patterns, e.g., for the same isotype/subclass and
antigen, levels were lower in infants than children and all
comparisons were p < 0.05 before adjustment for multiple testing.
We did not detect a significant influence of age on IgG2, IgG4, or
IgM levels in any group after the booster, except for NANP IgG4
levels in the R3R group that were higher in children. Likewise, we
did not detect significant differences in antibody levels against
HBsAg between age groups.
Malaria episodes. We compared the antibody levels at M20, M21
and M32 in individuals who had either presented or not with
clinical malaria before M20 (Figs. 5–7 and Supplementary Table 3).
None of the comparisons were statistically significant after
adjusting for multiple testing. At M20 we did not detect any
significant difference between individuals who presented or not
with prior clinical malaria in the RTS,S vaccinees. In the R3R group
at M21 there was a pattern for lower anti-CSP FL and anti-C-term
IgG, IgG1, IgG3, IgG4 and IgM levels, and anti-NANP IgG4 levels
(p < 0.05 before adjustment) in individuals who had clinical
malaria. For the R3C group at M21, individuals who presented
with clinical malaria before M20 had lower anti-CSP IgG and IgG1
mean levels against CSP antigens, and lower IgG3 levels against
CSP FL (p < 0.05 before adjustment). In contrast, IgM levels were
higher in plasma from previous malaria cases but this was not
statistically significant. In the C3C group, IgG and IgG1-3 to FL CSP
and NANP were higher in the subjects with previous malaria cases
but this difference was not statistically significant after adjusting
for multiple testing. Lower levels of IgG, IgG1, and IgG3 to HBsAg
were also observed in R3C at M20, M21, and M32 in the previous
Fig. 2 RTS,S/AS01E booster and long-term immunogenicity against vaccine antigens: IgG3-4 subclasses and IgM for CSP constructs and
HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with
medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3+ 1.5*IQR, lower whisker as the largest
between minimum × value and Q1 – 1.5*IQR, and log10(geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the
booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each
timepoint. Only p-values < 0.05 after adjustment for multiple testing are shown. The y-axis is in logarithm 10 scale. R3R (green): three doses of
RTS,S/AS01E and a RTS,S/AS01E booster. R3C (red): three doses of RTS,S/AS01E and a comparator booster. C3C (blue): three doses of a
comparator vaccine and a comparator booster.
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malaria cases (Supplementary Fig. 7), but these differences were
not statistically significant.
The study was not designed to assess associations with future
malaria risk but we had some provisional findings. IgG2 and IgG3 to
vaccine antigens in the R3R group at M21 were higher in those
subjects with subsequent clinical malaria, but this difference was
not statistically significant. Only for anti-NANP IgG2 and anti-HBsAg
IgG2 and IgG3 levels, differences had p < 0.05 before adjusting for
multiple testing (Figs. 8–11 and Supplementary Table 3). In contrast,
IgG1 and IgG4 levels to NANP and CSP FL in the R3R group at M21
were lower in malaria cases, but not significantly. An opposite
pattern consisting of higher levels in malaria cases was observed in
the R3C group. Fold-change in IgM levels against CSP constructs
from M20 to M21 in the R3R group was lower in malaria cases (p <
0.05 before adjustment) (Supplementary Figs. 8 and 9). This
contrasted to what was observed in the R3C group who had higher
fold-change in IgM levels in malaria cases. Additionally, the fold-
change in anti-HBsAg IgG3 levels was higher in malaria cases (p <
0.05 before adjustment). In most cases, there was no statistically
significant difference between subjects presenting with clinical
malaria after M21 and those who did not.
Effect of RTS,S booster vaccination on antibodies to blood stage
antigens
For most of the blood stage antigens we studied, we could not
detect differences in antibody levels before and after the booster
dose, nor when comparing the R3R, R3C, and C3C groups. There
were some differences (p < 0.05 before adjustment) in antibody
levels at M3 and/or M21 for MSP5, MSP142, MSP1-BL2, Rh4.2,
EBA140 and EBA175 (Supplementary Figs. 10–15 and Supplemen-
tary Table 4). Interestingly, Rh5 antibodies showed a consistent
change in levels after the RTS,S booster for IgG and all IgG
subclasses, with higher levels in the R3R group (Figs. 12 and 13;
Supplementary Fig. 16 and Supplementary Table 4). In the case of
IgG, IgG1 and IgG2 the differences were significant both in the
short (M21) and long (M32) term, while for IgG3 and IgG4
differences were only at M21 with p < 0.05 before adjustment.
Curiously, overall levels diminished over follow-up with the
exception of IgG4.
Age did not have a significant effect on the antibody levels
against the studied blood stage antigens (Supplementary Figs. 16–
23 and Supplementary Table 5). Individuals who were classified as
having had a case of clinical malaria before M20 tended to have
higher levels of antibody to blood stage antigens at M20-32 but
this difference was not statistically significant (Supplementary
Figs. 24–30 and Supplementary Table 6). The most remarkable
difference was the levels of MSP142 that acted as a marker for
malaria exposure, showing higher levels in those who had clinical
malaria, in particular for IgG, IgG1 and IgG2. Overall, the responses
showed a general pattern of higher levels at all time points for all
vaccination groups in individuals who subsequently presented
with a malaria case but it was not significant (Supplementary Figs.
31–37 and Supplementary Table 6).
DISCUSSION
This study confirms that the RTS,S/AS01E booster dose increases
total IgG levels against vaccine antigens and elucidates its
Fig. 3 Antibody responses against vaccine antigens for months (M) 0, 3, 20, 21, and 32 for IgG, IgG1, and IgG2. Boxplots with median,
interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3+ 1.5*IQR, and lower whisker as the largest
between minimum × value and Q1 – 1.5*IQR. The y-axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous
study in the same individuals7, thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01E and a RTS,S/AS01E booster at
month 20. R3C (red): three doses of RTS,S/AS01E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator
booster.
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differing effect on IgG subclasses and IgM not previously studied.
We describe for the first time the long-term RTS,S/AS01E antibody
response to different antigens and CSP epitopes. The booster dose
increased total IgG, IgG1, IgG3, and IgG4 for all vaccine antigens
compared to pre-booster levels, and they remained above the
levels of non-vaccinated individuals during the entire follow-up
period. Remarkably, the fourth dose did not induce an increase in
IgG2 levels (although the primary vaccination did) but it increased
IgG1 and IgG3 levels, which may explain how the booster led to
higher efficacy overall. IgG1 and IgG3 can effectively fix
complement and promote interactions with Fcγ-receptors on
phagocytes10, which could be contributing to RTS,S-induced
protection. IgG2 and IgG4, on the contrary, are non-cytophilic
antibodies unable to fix complement and to interact with Fcγ-
receptors10.
The profile of antibody responses seems to be epitope-specific.
Previously, the bulk of studies had only evaluated NANP
antibodies and have provided clear evidence that NANP
antibodies are associated with protection6, being the established
immunodominant region of the vaccine antigen4. However, there
is evidence that antibodies against C-term are involved in
phagocytic activity in US naive adults13, and RTS,S vaccine-
induced antibodies to the C-term among children can promote
complement fixation14. Also, in our previous work we have found
that post-primary vaccination, the avidity of the IgG response to
CSP C-term was associated with protection12. Here, we show that
the booster dose increases levels of antibodies against both NANP
and the C-term, and that the responses against these two regions
may behave differently. Antibody levels to NANP were higher
compared to C-term, but the proportional increase 1 month after
the booster dose was not different.
Previously it was reported that the IgG levels to NANP were
increased by the booster dose, but the peak post-booster levels
were lower than following primary vaccination6. In this study, we
found similar results for IgG subclasses—there was boosting but
levels overall were lower than following primary vaccination7.
Remarkably, IgG4 levels against CSP kept increasing with time. The
RTS,S pattern differs to other vaccines in which the peak for the
booster response is higher than the peak for the primary
vaccination18. The unusual response to the booster dose could
be caused by different factors. These factors include the response
to primary vaccination19, but also the booster dose or the primary
vaccination schedule20,21. For instance, it has been reported that
for some vaccines high residual levels of vaccine antibodies have a
negative effect on the post-booster response19; however, our
study did not find evidence for a negative correlation between
M20 and M21 antibody levels (Supplementary Figs. 38 and 39).
There is also evidence from the response to a Meningococcal
conjugated vaccine that primary vaccination administered with a
short interval doses might lead to higher antibodies at the primary
vaccination peak, but a higher number of doses lead to a lower
post-booster response20. The effect of the dosing interval on the
responses to the RTS,S vaccine was observed on a phase 2 trial
that compared a 0, 1, 2 months vs. 0, 1, 7 months schedule and
showed that the highest peak was observed following the 0, 1,
2 month schedule21. Also, the booster dose might induce different
IgG subclass patterns to primary vaccination because it is acting
on immune memory cells such as B memory cells and it might be
inducing class switch and increasing antibody affinity19,22.
Fig. 4 Antibody responses against vaccine antigens for months (M) 0, 3, 20, 21, and 32 for IgG3, IgG4 and IgM. Boxplots with median,
interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3+ 1.5*IQR, and lower whisker as the largest
between minimum × value and Q1 – 1.5*IQR. The y-axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous
study in the same individuals [7], thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01E and a RTS,S/AS01E booster at
month 20. R3C (red): three doses of RTS,S/AS01E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator
booster.
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The AS01E adjuvant and the innate response and cytokine milieu
that it elicits likely affect the evolution of antibody subclass
patterns observed. In addition, it may be influenced by differences
in immune development due to older age and environmental
exposures19. For instance, it has been reported that malaria
transmission affects the antibody subclasses patterns in subjects
who had malaria episodes23. Nevertheless, it is important to note
that because primary and booster antibody data were not
analyzed at the same time, the comparison of antibodies between
time points in our study should be interpreted carefully.
We are reporting for the first time the antibody booster
response against HBsAg. Although the booster dose did increase
IgG, IgG1, IgG3 and IgG4 antibodies, the increments were lower
than those of anti-CSP antibodies, and were similar to the
response induced by primary vaccination in the Manhiça site7.
Interestingly, the results of a trial that analyzed the response to a
hepatitis B vaccine booster after RTS,S primary vaccination
showed an increased response in HBsAg IgG concentrations
compared to primary vaccination24. The responses to HBsAg may
be an indication of the quality of the immune response or the
immune status of the child and the capacity to respond to
vaccination and it requires further investigation.
It has been previously reported that antibodies after primary
vaccination are lower in the infant group than in the children
group. This may be due to the interference of maternal antibodies
against CSP or intrinsic differences in the developing and
functional competence of the immune system5. Antibodies seem
to be lower in infants than children also at months 20, 21, and 32
but only for total IgG and IgG1 against CSP epitopes, not for
HBsAg responses, even though maternal antibodies are no longer
present at this age. At the time of the booster, both age groups
have passed the critical age of 2 years for immune ontogeny and
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Fig. 5 Immunogenicity for CSP FL stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32
for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20,
subjects who presented with clinical malaria (M= blue) and subjects without malaria (NM= red). Boxplots with medians, interquartile ranges
(IQR), upper whisker as the smallest between maximum× value and Q3+ 1.5*IQR, lower whisker as the largest between minimum × value and
Q1 – 1.5*IQR, and log10(geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria
(M vs. NM). p-values were adjusted for multiple comparisons, but none was significant. Only p-values < 0.05 before adjustment are shown. The
y-axis is in logarithm 10 scale. R3R: three doses of RTS,S/AS01E and a RTS,S/AS01E booster. R3C: three doses of RTS,S/AS01E and a comparator
booster. C3C: three doses of a comparator vaccine and a comparator booster.
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their immune system has achieved a more adult status25,26,
therefore, major differences driven by intrinsic changes in the
immune system are less likely at this timepoint. Instead,
differences detected may reflect a distinct establishment of a
memory response in infants and children after primary vaccination
that differentially affects the boosting of responses.
One of the factors identified thus far in this and our previous
studies7, with an impact on vaccine responses, is prior malaria
exposure. Preceding malaria cases were associated with lower IgG,
IgG1, and IgG3 levels to CSP constructs at the time points studied.
How malaria episodes may affect immunization outcomes is
another key issue, since it may affect any malaria vaccine and
needs to be addressed in follow-up studies.
The study was not powered to assess association of antibodies
with malaria risk but we obtained some preliminary findings.
Interestingly, in children with malaria episodes post-booster dose,
the IgG2 and IgG3 levels at M21 were higher than non-malaria
controls, while IgG, IgG1, and IgG4 levels were lower, although
with the available sample size this was not statistically significant
for most comparisons. These results are in line with the findings of
our previous study7 in which IgG2 levels to RTS,S antigens were
higher in malaria cases than in controls, whereas IgG1 levels were
lower. The booster dose might be increasing protection not only
by increasing total IgG levels, but also by not inducing IgG2 that
could be detrimental, or not protective according to our previous
results. However, the tendency for malaria cases to be associated
with higher levels of IgG3 and lower levels for IgG4 to CSP
constructs was opposite to what was reported to occur after
primary vaccination7 where a higher ratio between cytophilic
(IgG1 and IgG3) to non-cytophilic (IgG2 and IgG4) CSP antibodies
was associated with protection. The association between IgG4
levels and protection is consistent with findings of Chaudhury
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Fig. 6 Immunogenicity for CSP NANP stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and
32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20,
subjects who presented with clinical malaria (M= blue) and subjects without malaria (NM= red). Boxplots with medians, interquartile ranges
(IQR), upper whisker as the smallest between maximum × value and Q3+ 1.5*IQR, lower whisker as the largest between minimum × value and
Q1 – 1.5*IQR, and log10(geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria
(M vs. NM). p-values were adjusted for multiple comparisons, but none was significant. Only p-values < 0.05 before adjustment are shown. The
y-axis is in logarithm 10 scale. R3R: three doses of RTS,S/AS01E and a RTS,S/AS01E booster. R3C: three doses of RTS,S/AS01E and a comparator
booster. C3C: three doses of a comparator vaccine and a comparator booster.
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et al.27 who reported that only IgG4 levels were positively
associated with increased vaccine efficacy in malaria-naive adults
under the fractional dose regime. We have also previously found
an association between IgG4 responses to non-RTS,S antigens
after primary vaccination and protection8. IgG4 antibodies are
associated with repeated or long-term exposure to antigens and
have been linked to induction of tolerance, for instance higher
IgG4/IgE ratios are associated with better food tolerance, as IgG4
competes with IgE28. In the context of helminth infections, high
IgG4 is associated with asymptomatic infection for some
parasites10. However, there is conflicting evidence on the role of
IgG2 and IgG4 on protection against malaria, whilst more
information exists on the protective role of IgG1 and IgG3. In
the context of naturally acquired immunity, the ratio of cytophilic
(IgG1+ IgG3) to non-cytophilic subclasses (IgG2+ IgG4) is gen-
erally higher in subjects with uncomplicated malaria compared to
subjects with complicated malaria, and higher in subjects
protected from malaria7,29. Additionally, it has been reported that
the IgG2/IgG4 ratio is higher in subjects with uncomplicated
malaria30. However, it has also been observed that IgG2 and IgG4
with high avidity are found in subjects with uncomplicated
malaria compared to complicated malaria29. In contrast, the
Chaudhury et al.27 study assessing avidity and opsonization
reported that RTS,S protection was mediated by IgG4 against the
C-term of CSP. All of this evidence indicates that not only antibody
levels are important for protection but also the balance between
subclasses.
We note that the pattern of higher IgG, IgG1, and IgG4 levels to
CSP FL and C-term in non-malaria cases was not apparent
for NANP.
We previously observed that after primary vaccination, HBsAg
antibody responses were associated with malaria protection7,12.
Previous malaria cases
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Fig. 7 Immunogenicity for CSP C-term stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21,
and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before
M20, subjects who presented with clinical malaria (M= blue) and subjects without malaria (NM= red). Boxplots with medians, interquartile
ranges (IQR), upper whisker as the smallest between maximum × value and Q3+ 1.5*IQR, lower whisker as the largest between minimum ×
value and Q1 – 1.5*IQR, and log10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical
malaria (M vs. NM). p-values were adjusted for multiple comparisons, but none was significant. Only p-values < 0.05 before adjustment are
shown. The y-axis is in logarithm 10 scale. R3R: three doses of RTS,S/AS01E and a RTS,S/AS01E booster. R3C: three doses of RTS,S/AS01E and a
comparator booster. C3C: three doses of a comparator vaccine and a comparator booster.
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On the contrary, 1 month after receiving the RTS,S booster dose,
anti-HBsAg IgG2 and IgG3 levels appeared as risk factors for future
malaria episodes, further indicating that the nature and role of
responses may differ following a primary and a booster
immunization.
The analysis of the phase 3 clinical trial found that children who
did not receive the booster dose were at higher risk of severe
malaria than the comparator (non-RTS,S) group3. It was hypothe-
sized that the primary vaccination had prevented vaccinees from
acquiring natural immunity, as has been predicted for other
malaria prevention tools16, increasing the risk of severe malaria in
those individuals in whom infection reached the erythrocytic
stage. However, on a longer follow-up study of up to 7 years on 3
of 11 sites, no increased risk was found for severe malaria between
those groups that received the RTS,S/AS01 vaccine and the control
group31. Antibody responses to asexual blood stage antigens have
been studied previously with samples from phase 2 clinical trials
and showed a reduced antibody response in RTS,S vaccinees, but
these trials did not include a booster dose17,32,33. We detected a
decreased antibody response to certain vaccine-unrelated
P. falciparum antigens after primary vaccination in the phase 3
trial as well8,9. However, we also observed an induction of
antibody responses to other P. falciparum antigens following RTS,S
vaccination (MSP1-BL2, EBA140, EBA175, and Rh4.2), which could
contribute to malaria protection8,9. Here, we did not find
consistent differences in the NAI response between booster
groups except for Rh5. Interestingly and in line with our previous
results, Rh5 IgG and IgG1-2 levels were higher in the RTS,S booster
group than in the comparator vaccine groups at M21 and M32,
and R3C levels were either higher or did not differ from C3C.
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Fig. 8 Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP FL at month (M) 20, 21, and
32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects
who presented with clinical malaria (M= blue) and subjects without malaria (NM= red). Subjects who presented with clinical malaria before
M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest
between maximum × value and Q3+ 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log10 (geometric
mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p-values were adjusted
for multiple comparisons, but none was significant. Only p-values < 0.05 before adjustment are shown. The y-axis is in logarithm 10 scale. R3R:
three doses of RTS,S/AS01E and a RTS,S/AS01E booster. R3C: three doses of RTS,S/AS01E and a comparator booster. C3C: three doses of a
comparator vaccine and a comparator booster.
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This finding requires future investigation to understand the basis
and clinical relevance of this effect, especially since Rh5 is a
leading vaccine candidate34, and because Rh5 antibody concen-
trations need to be very high to actually confer protection35.
However, these observations are important as they may explain
why an anti-sporozoite infection vaccine also protects against
clinical disease in the parasite blood stage, considering that Rh5
plays an essential role during erythrocyte invasion by P. falciparum
merozoites36–38. Additionally, IgG to MSP5 showed higher levels
after RTS,S booster dose compared to the comparator booster
group, but this was not statistically significant.
Our findings are limited because of a small sample size and
because data were obtained only for Manhiça. Therefore, a larger
longitudinal study with samples from different sites is necessary to
corroborate these data. This is particularly important in our case
because there are some special considerations about Manhiça that
limits the generalization of these findings: (1) at the time of the
study malaria transmission was low3,39, (2) there were unexpected
results of VE in the phase 3 clinical trial, i.e., VE was lower in the
R3R than in the R3C group, contrary to most sites, and (3) Manhiça
has a high HIV prevalence40. HIV infection was associated with a
reduced immunogenicity to the vaccine in a phase 3 trial
exploratory analysis but it was concluded that HIV-infected
children should not be excluded from RTS,S vaccination41.
Despite the constraints, our study provides new and interesting
clues to the immune response elicited by the RTS,S booster dose.
Additionally, avidity and functional antibody responses should be
assessed, and these results integrated with cellular data to address
memory responses induced by the booster. This information is
necessary for a deeper understanding of the mechanisms of
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Fig. 9 Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP NANP at month (M) 20, 21,
and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21,
subjects who presented with clinical malaria (M= blue) and subjects without malaria (NM= red). Subjects who presented with clinical malaria
before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest
between maximum × value and Q3+ 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log10(geometric
mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p-values were adjusted
for multiple comparisons, but none was significant. Only p-values < 0.05 before adjustment are shown. The y-axis is in logarithm 10 scale. R3R:
three doses of RTS,S/AS01E and a RTS,S/AS01E booster. R3C: three doses of RTS,S/AS01E and a comparator booster. C3C: three doses of a
comparator vaccine and a comparator booster.
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action of the vaccine, as well as the determination of the factors
causing partial and short VE. Results of these studies are required
for the rational design and deployment of improved CSP-based
vaccines and other malaria vaccines with an increased and long-
term efficacy.
METHODS
Population and study design
This study was performed using plasma samples previously collected from
subjects in Manhiça, Mozambique, a site of low malaria transmission
intensity3,39, as part of the MAL067 study ancillary to the phase 3
randomized clinical trial MAL055 (NCT00866619)3. A subset of 50
individuals (24 children 5–17 months and 26 infants 6–12 weeks) was
selected from those previously analyzed7–9 who had available antibody
data from M0 (baseline) and M3 (one month after third dose) and plasma
samples for M20 (booster dose), M21, and M32 (Supplementary Table 7).
The subjects had either received three doses of the RTS,S/AS01E vaccine
and a RTS,S/AS01E booster (R3R, n= 14) at M20, three doses of RTS,S/AS01E
and a comparator booster (R3C, n= 19), or three doses and a booster of a
comparator vaccine (C3C, n= 17) (Supplementary Fig. 40). The comparator
vaccines used in the primary series were a Meningococcal C Conjugate
Vaccine (Menjugate™) in the 6–12 weeks age category, and a cell-culture
rabies vaccine (VeroRab™) in the 5–17 months age category. The booster
comparator was Menjugate™ for both age groups. Clinical malaria cases
were detected by passive case detection and defined as fever of at least
37.5 °C and any asexual P. falciparum parasitemia by microscopy3. The
prevalence of HIV infection in the Manhiça area was around 40% in
adults40. HIV infection was not a protocol exclusion/inclusion criteria, but
only healthy children were included in the study. HIV testing was not a trial
procedure. The study protocol was approved by the Ethics Committees of
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Fig. 10 Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP C-term at month (M) 20, 21,
and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21,
subjects who presented with clinical malaria (M= blue) and subjects without malaria (NM= red). Subjects who presented with clinical malaria
before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest
between maximum × value and Q3+ 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log10(geometric
mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p-values were adjusted
for multiple comparisons, but none was significant. Only p-values < 0.05 before adjustment are shown. The y-axis is in logarithm 10 scale. R3R:
three doses of RTS,S/AS01E and a RTS,S/AS01E booster. R3C: three doses of RTS,S/AS01E and a comparator booster. C3C: three doses of a
comparator vaccine and a comparator booster.
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PATH-MVI (REC) in the US, Hospital Clínic in Spain (CEIm) and the CNBS in
Mozambique, and written informed consent was obtained from parents or
guardians before recruitment.
Antibody luminex assays
Antibody response was analyzed using a quantitative suspension array
technology (qSAT). MAGPlex beads were coupled separately to: three CSP
constructs (FL, C-term, NANP-repeat region) and HBsAg that are antigenic
components of the RTS,S vaccine; seven P. falciparum blood stage antigens
(MSP1 [block 2 and MSP142 fragments, 3D7 strain], MSP5, EBA140, EBA175
region 3-5, Rh4.2 and Rh5) that were shown to be affected by vaccination
in our previous studies7–9 and/or that are leading vaccine candidates; and
Glutathione S-transferase (GST) as a control for antigens co-expressed with
a GST tag (Supplementary Table 8)42. The coupling of the beads to the
antigens was performed as described previously43.
Antigen-coupled beads were added to a 96-well μClear® flat bottom
plate (Greiner Bio-One) in multiplex (1000 microspheres/analyte/well)
resuspended in 50 μL of PBS, 1% BSA, 0.05% Azide pH 7.4 (PBS-BN). Fifty
microliters of sample, negative or positive control were added to wells and
incubated overnight at 4 ºC in a shaker protected from light. Plates were
washed three times with 200 μL/well of wash buffer (PBS-Tween 20: 0.05%)
using a manual magnetic washer. Then, 100 μL of biotinylated secondary
antibody were added diluted in PBS-BN: anti-human IgG 1/2500 (B1140
Sigma), anti-human IgG1 1/4000 (ab99775 Abcam), anti-human IgG3 1/
1000 (B3523 Sigma), and anti-human IgM 1/1000 (B1265 Sigma). For IgG2
and IG4, mouse anti-human IgG2 1/500 and IgG4 1/500 (MA1-34755 and
MA5-16716 Thermo Fisher), respectively, were added, followed by
biotinylated goat anti-mouse IgG 1/40,000 for IgG2 and 1/10,000 for IgG4
(B7401 Sigma) in PBS-BN. All antibody incubations were performed for
45min, at room temperature, in agitation and protected from light. Again,
plates were washed as before and 100 μL/well streptavidin-R-phycoerythrin
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Fig. 11 Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for HBsAg at month (M) 20, 21, and
32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects
who presented with clinical malaria (M= blue) and subjects without malaria (NM= red). Subjects who presented with clinical malaria before
M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest
between maximum × value and Q3+ 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log10(geometric
mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p-values were adjusted
for multiple comparisons, but none was significant. Only p-values < 0.05 before adjustment are shown. The y-axis is in logarithm 10 scale. R3R:
three doses of RTS,S/AS01E and a RTS,S/AS01E booster. R3C: three doses of RTS,S/AS01E and a comparator booster. C3C: three doses of a
comparator vaccine and a comparator booster.
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1/1000 (42250 Sigma) in PBS-BN was added to all wells and incubated
30 min, at room temperature, in agitation and protected from light.
Plates were washed as before and resuspended in 100 μL/well of PBS-BN.
Plates were stored at 4 °C overnight protected from light and read the
next day using the Luminex xMAP® 100/200 analyzer; at least 50
microspheres per analyte were acquired per sample and Report Gain was
set as High PMT.
For IgG, IgG1, IgG3, and IgM, 20 serial dilutions 1:2 of a positive control
were used to perform antigen-subclass-specific standard curves. For IgG2,
16 serial dilutions 1:2 were used. For IgG4, no standard curve was
performed and only one positive control dilution was included. The
positive control consisted of a WHO Reference Reagent for anti-malaria
P. falciparum human serum (NIBSC code: 10/198)42,44 at 1:50 mixed with a
pool of plasmas from RTS,S/AS02 vaccinated children42,45 with high IgG
levels against CSP at 1:200. Blanks were added to each plate in duplicates
and two negative controls samples from malaria-naive adults were added
in each plate. Test samples were assayed at three dilutions for IgG (500,
20,000, 500,000), IgG1, IgG3 (100, 2500, 100,000) and IgM (100, 1000,
25,000) to ensure that at least one dilution lie in the linear range of the
respective standard curve, i.e., close to the highest slope between two
dilution points. Owing to the low levels previously observed in these
samples for IgG2 and IgG4 in Ubillos et al.7 only one dilution (1/50) was
used. Sample distribution across plates was designed to ensure a balanced
distribution of vaccination groups, sex, age cohorts, and malaria cases. The
three time points for each individual and the respective dilutions were
placed on the same plate. Data were captured using xPonent software, and
antibody levels were measured as MFI.
Data pre-processing. The standard curve for each antigen-isotype/
subclass-plate was estimated using the drLumi R package flow46, fitted
in a 4- or 5-parameter logistic (4-PL or 5-PL) regression model, and data
points logarithmically transformed. To select the sample dilution for IgG,
IgG1, and IgG3 in the linear part of the sigmoidal curve (antigen, isotype/
subclass and plate specific), an algorithm that detects the two points with
the highest slope between them was used. The slope was computed as:
m= (MFIi –MFIi+1)/(dilution_factori– dilution_factori+1). The mean MFI
value of the two points was computed and used as the reference value,
but the standard curves were visually inspected and if the model did not
converge, the R2 < 0.9 or the curve maximum values were < 15,000 MFI, a
15,000 MFI reference value was set instead of the highest slope criteria.
The nearest MFI of the test sample to the reference value was determined
and the corresponding dilution was selected. Since only one dilution was
used for IgG2 and IgG4, the standard curves were not used to select a
dilution. The MFI measurement of the selected dilution was corrected
multiplying by its corresponding dilution factor and transformed to log10
scale to stabilize the variance. Blank and GST signals were not subtracted.
Blanks were used to measure background signal, and GST to assess for
unspecific binding to the GST-fused antigens (CSP FL, CSP C-term, and CSP-
NANP). Background values were below 500 MFI, and no correlation was
found between IgG to GST and IgG to GST-fused antigens (Supplementary
Figs. 41 and 42).
Statistical analysis
Descriptive comparisons of Ig isotype/subclass levels to specific antigens
(log10 transformed MFI) at each visit were done by boxplots with
log10(geometric mean), medians, interquartile ranges (IQR), upper whisker
as the smallest between maximum× value and Q3+ 1.5*IQR and lower
whisker as the largest between minimum× value and Q1 – 1.5*IQR.
Wilcoxon-Signed Rank Test between M20 and M21 for the R3R vaccination
group, and between M21 and M32 for the R3R and R3C vaccination groups
were performed to determine if the antibody levels changed significantly
1 month and 1 year after the booster. Additionally, Mann–Whitney tests
were performed to compare the R3R and R3C groups at each timepoint.
Fig. 12 RTS,S/AS01E booster and long-term immunogenicity against the blood stage antigen Rh5: total IgG, IgG1-4 subclasses and IgM at
month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians,
interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3+ 1.5*IQR, lower whisker as the largest between
minimum × value and Q1 – 1.5*IQR, and log10(geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster
response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint.
Only p-values < 0.05 after adjustment for multiple testing are shown. The y-axis is in logarithm 10 scale. R3R (green): three doses of RTS,S/
AS01E and a RTS,S/AS01E booster. R3C (red): three doses of RTS,S/AS01E and a comparator booster. C3C (blue): three doses of a comparator
vaccine and a comparator booster.
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p-values were adjusted for multiple testing using p.adjust on R47 by the
Holm approach for IgG and for IgM to control for family wise error, and by
the Benjamini–Hochberg approach for IgG1-4, altogether to control for the
false-discovery rate since there were more tests. The comparisons between
time points were corrected separately from the comparisons between
vaccination groups, likewise the comparisons for vaccine antigens were
corrected separately from blood stage antigens. Data for M0 and M3 from
our previous study7 was used to analyze the kinetics of the antibody
response throughout the 5 time points in the clinical trial. Adjusted p-
values were considered significant when <0.05. The qSAT assay of M20,
M21, and M32 samples was performed in the same laboratory using the
same reagents and under similar conditions as the assay of the M0 and
M3 samples, but they were not executed at the same time and a smaller
set of antigens was used.
Stratified analyses and Mann–Whitney tests for independent groups and
Wilcoxon-Signed Rank Tests for paired samples were performed between
age groups and between malaria cases and controls, for each timepoint. p-
values were adjusted following the same strategy as above. There were no
reported malaria cases between M20 and M21. The change in antibody
levels between M20 and M21 was calculated as log10MFI(M21) – log10MFI
(M20) and compared between individuals who either did or did not
present with clinical malaria after M21. All data analysis and plots were
performed using R packages gridExtra48, dplyr49, ggplot250, tidyr51, and
psych52.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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